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ABSTRACT 
Objective: - To analyse the rationality of various FDCs used in the treatment 
Diabetes Mellitus and to find out the irrational FDCs existing in Indian 
market. Material and Methods: - Study Design: Analytical study. Data on 
FDC’s available in the Indian market was collected from Current Index of 
Medical Specialities (CIMS) and Monthly Index of Medical Specialities 
(MIMS) and their rationality was analysed using a pretested tool based on 
FDCs listed in WHO essential list of medicines and National List of Essential 
Medicines (NLEM), others based on their pharmacodynamic activity, 
Pharmacokinetic parameters and significant drug interactions occurring due 
to API (Active pharmaceutical ingredients) contained within the product 
Result: A total of 18 combinations were analysed, among those 11 
combinations were irrational. Conclusion: Predominantly irrational FDCs are 
being circulated in the Indian market hence through analyses by prescribers 
is needed before prescribing to patients in order to avoid ADR. This calls for 
a close scrutiny of marketed FDCs and educating prescribers to use them with 
great care and caution also indicates a serious review of regulatory 
framework for drug manufacturing and marketing. 
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INTRODUCTION  
Diabetes mellitus (DM), commonly referred to as diabetes 
is a group of metabolic diseases in which there are high 
blood sugar levels over a prolonged period. Globally, an 
estimated 422 million adults are living with diabetes 
mellitus, according to the latest 2016 data from the World 
Health Organization (WHO) [1]. 
Fixed dose combinations (FDCs) refer to products 
containing two or more active drugs used in a single 
dosage form for a particular indication [2].  Prescribing 
Fixed Dose Combinations (FDCs) in Diabetes mellitus 
treatment is a routine practice.  Although FDCs are 
associated with many advantages like synergistic action, 
reduced adverse effects, reduced pill burden, cost of the 
treatment and improved patients compliance [3] but 
certain disadvantages like incompatible 
pharmacokinetics, inflexible dose ratio and increased 
toxicity are limiting factors.  
FDC is acceptable when the combination has proven 
advantage over single compound administered separately 
in terms of therapeutic efficacy or safety [4] Considering 
better patient compliance more and more physicians 
favour FDCs. As a result, pharmaceutical companies 
utilize this golden opportunity and market more and more 
combinations of which many of them are irrational. 
MATERIALS & METHODS 
Study Design:  observational and Analytical study 
Sample: Data on FDC’s available in the Indian market 
was collected from Current Index of Medical Specialities 
(CIMS) and Monthly Index of Medical Specialities 
(MIMS). 
Methods: Rationality was analysed using a pretested tool 
based on FDCs listed in WHO essential list of medicines 
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& national list of essential medicines (NLEM) - on their 
pharmacodynamic activity, Pharmacokinetic parameters 
& significant drug interactions occurring due to API 
(Active pharmaceutical ingredients) contained within the 
product [5,6].  
Analysis: All the quantitative variables have been 
expressed as mean and standard deviation and qualitative 
variables are expressed as percentages and proportions. 
RESULTS  
Total 18 FDCs were analysed. It was observed that 7 of 
the FDCs in antidiabetes drugs meet the criteria for 
rationality but there are 11 combinations found to be 
irrational. 
Glibenclamide + metformin  
Gliclazide + metformin 
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Glimipride +metformin 
Glimipride + metformin + pioglitazone 
Glipizide + metformin 
Glibenclamide + metformin + pioglitazone 
Glibenclamide + metformin + volgibose 
Glimipride + metformin + Ramipril 
Glimipride + metformin + Ramipril + atrovastatin 
Glimipride + metformin + atrovastatin 
Metformin + fenofibrinate 
 
Fig 1. Shows the rational and irrational FDC 
 
Fig 2. Shows percentages of different FDC’s          
used irrationally  
DISCUSSION 
Sulfonylureas + Biguanides:  
Pharmacokinetics: After oral administration, glimepiride 
is completely (100%) absorbed from the GI tract. Studies 
with single oral doses in normal subjects and with multiple 
oral doses in patients with Type 2 diabetes have shown 
significant absorption of glimepiride within 1 hour after 
administration and peak drug levels (Cmax) at 2 to 3 
hours. When glimepiride was given with meals, the mean 
Tmax (time to reach Cmax) was slightly increased (12%) 
and the mean Cmax and AUC (area under the curve) were 
slightly decreased (8% and 9%, respectively) [7].  
Absorption of sulfoylureas is delayed by food and 
hyperglycemia 
In view of time required to reach an optimal concentration 
in plasma, sulfonylureas are more effective when given 
30min before food [8]. 
Antidiabetic + Antihypertensive + Hypolipidimics 
A study conducted by Nisharan et. Al. showd that FDC 
when given in combination did not reach peak action of 
metformin, atrovastatin, and absorption of the metformin 
was reduced to only 80%, and delayed the absorbtion time 
which indicated the presence of interaction between these 
components [9]. 
They also violate some of the principles of formulation of 
FDCs like; 
a. Increased efficacy in comparison to the individual 
components given at the same dose,  
b. The incidence of adverse reactions in response to 
treatment with the combination is lower than in that in 
response to any of the component actives given alone, 
c.  Improved adherence, simplified therapy,  
d. the actives in a combination should have similar 
pharmacokinetics. [10]. 
CONCLUSION 
To conclude around 62% of the FDCs were found 
irrational. Indeed, it is very unfortunate and unethical to 
expose the innocent patients to medicines with unproven 
efficacy and safety. This calls for a close scrutiny of 
marketed FDCs and educating prescribers to use them 
with great care and caution. This also indicates a serious 
review of regulatory framework for drug manufacturing 
and marketing. 
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